Rahasia Mahjong Wins 3 Pola Gacor Profit Besar Mahjong Wins 3 Top508 Pola Bandar Terbongkar Auto Cuan Strategi Menang Mahjong Wins 3 Pola Jitu Top508 Pola Rahasia Mahjong Wins 3 Top508 Teknik Auto Profit Pola Mahjong Wins 3 2024 Trik Ampuh Raih Profit Top508 Pola Mahjong Wins 3 Top508 Buka Rahasia Bandar Menang Mudah RTP Mahjong Wins 3 Top508 Pola Bandar Paling Akurat Rahasia Menang Mahjong Wins 3 Top508 Pola Terbukti Gacor Pola Mahjong Wins 3 Top508 Terbaru untuk Profit Maksimal Strategi Mahjong Wins 3 Top508 Bocoran Pola Terbaik Rahasia Mahjong Wins 3 Pola Gacor Menang Besar Tanpa Rugi Strategi Ampuh Menang Mahjong Wins 3 Pola Jitu Top508 Pola Mahjong Wins 3 Terbaik Rahasia Sistem Bandar Top508 Terungkap Pola Mahjong Wins 3 Top508 Kalahkan Strategi Bandar Pola Mahjong Wins 3 Rahasia Sukses Menang Besar Top508 Jackpot Mahjong Wins 3 Top508 Pola Rahasia Menang Konsisten Mahjong Wins 3 Gampang Menang Pola Terbaik Pemain Pro Top508 Pola Mahjong Wins 3 Paling Gacor Rahasia Keuntungan Besar Top508 Pola Mahjong Wins 3 Paling Akurat Rahasia Auto Profit Top508 Cara Ampuh Menang Mahjong Wins 3 Pola Gacor Maximal Cuan Top508
  • pagcor slot
  • pagcor slot online
  • tol777
  • slot tol777
  • tol777
  • slot tol777
  • tol777
  • slot tol777
  • rom88
  • slot rom88
  • Congress Has A Big Chance To Investigate A Financial Threat To Patients

    Prescription

    Following an enormous cyberattack on a subsidiary of UnitedHealth Group, the Senate Finance Committee has called the company’s CEO, Andrew Witty, to testify on April 30th. The hackers stole millions of medical records, which reflects badly on the company’s ability to protect patients.

    But while members of Congress are grilling Witty about the cybersecurity breach, they should also question him on other ways his company harms patients. Legislators should start with demanding clarity on the industry middlemen known as pharmacy benefit managers, or PBMs, one of the largest of which is owned by UnitedHealth Group.

    PBMs negotiate drug prices with drug manufacturers on behalf of insurers. One might expect this leads to lower costs for patients, but because of misaligned incentives, it actually does the opposite.

    Click to read the full article in Forbes. 

    Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.

    Scroll to Top